Refine by
Tumor Immune Suppliers & Manufacturers
55 companies found
based inNew York, NEW YORK (USA)
ENB is developing platform oncology molecules to unlock the full therapeutic potential of immune-based cancer therapies. We are developing small molecules that turn off a common “switch” that activates critical pro-cancer components of the TME: the ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
based inCambridge, MASSACHUSETTS (USA)
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of ...
BOS-371 is a highly potent monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a prevalent tumor associated antigen driving tumor growth and immunosuppression. BOS-371 has also been Fc-engineered to enhance effector ...
based inKaty, TEXAS (USA)
CLOUD-CLONE CORP. (CCC), a research and experimental development in molecular biology and immunology oriented company headquartered in Houston, focuses on production of assay reagent, manufacture of analysis equipment and service for animal ...
based inxiamen, CHINA
XIAMEN SPACEGEN Co., Ltd. is a high-tech molecular diagnostic biology enterprise integrating R&D, production, sales and service. The company leads technological innovation guided by clinical needs ,providing high-quality and accessible molecular ...
Using high-throughput sequencing to test the coding regions and exon-intron junctions of five genes (MLH1, PMS2, MSH2, MSH6, EPCAM) in the germline panel, and the same five genes plus the BRAF V600E mutation in the tissue-based panel. Detection ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ gamma delta T ...
based inBerlin, GERMANY
JPT Peptide Technologies GmbH is a leading provider of custom peptides and innovative peptide-based services and products. We are a research and development partner for projects in immunotherapy and vaccine Development, immune monitoring, proteomics ...
PepSup is a highly standardized, peptide-based cell activation (cell stimulation) assay designed to produce short-term culture supernatants for analysis of cytokines or other mediators of interest. We create your PepSup Cell Activation Kit with your ...
based inNewark, DELAWARE (USA)
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across ...
IL-15,Interleukin-15,IL15,Interleukin ...
based inBrea, CALIFORNIA (USA)
We are pleased to announce the exclusive commercialization and sale of KinesisDx product lines to Krishgen Biosystems, India for worldwide usage effective July 11, 2019. This is in line with our philosophy to partner with forward looking companies ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
ALG.APV-527 is a bispecific antibody candidate targeting 4-1BB x 5T4 and is intended for tumor-directed treatment of solid cancers. It was built using Aptevo’s ADAPTIR™ bispecific technology platform and combines binding domains sourced ...
based inRancho Dominguez, CALIFORNIA (USA)
DxTerity is a patient-centric genomics company passionate about putting patients with immune-mediated diseases at the center of everything that we do. We’re harnessing the power of real-world genomics with convenient from-home RNA monitoring to help ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a ...
based inBasel, SWITZERLAND
CanVirex is a spin-off from the Heidelberg University Hospital, founded in 2017 in Basel, Switzerland. The company develops novel immunotherapeutics for the treatment of cancer and has recently committed to using its unique technology to develop a ...
Oncolytic measles viruses as a multiplexed immune-modulating platform for cancer therapy. Cancer remains a medical and social burden worldwide despite several technological advances in the past decades. Conventional cancer ...
based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Focusing initially on breast cancer, BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight cancer. ...
Bria-IMT™ (developed from a breast cancer cell line) is a patented (USPTO) immunotherapy approach that directly stimulates the body’s own cancer fighting cells to attack and destroy breast cancer tumors. ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
Ushering in the Future of NK-cell Therapy: Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet to be proven. The cell platform and novel targeting ...
based inBroomfield, COLORADO (USA)
Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and ...
For rapid and precise cancer care, pathologists and oncologists need dependable diagnostic testing to connect patients to individualized immuno-oncology therapies. Flagship’s TissueInsight® diagnostic service offers you access to robust, ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Through the safe and efficient delivery of a novel ...
based inEpalinges, SWITZERLAND
AC BioScience Ltd., a clinical-stage biotech company and a developer of immune modulating and angiogenic cancer therapies. AC BioScience LTD. is a Swiss biotech company, pioneering the development of novel therapies in immuno-oncology and tumor ...
Our patented Beta-carboline derivative (ACB1801) is an actin dynamic modulator which induces cellular F-actin network remodeling (tumor reversal); this in turn translates into immuno-competency that allows the ...
based inMünchen, GERMANY
We are an interdisciplinary team with a focus on research, translation, clinical development, manufacturing, and commercialization. Our passionate team is committed to provide safe and effective tumor therapy. We are supported by a strong scientific ...
The FUSIX technology is based on a hybrid virus construct combining all the advantages of both parental platforms while minimizing risks factors. This results in an oncolytic virus platform with an excellent safety profile and effective replication ...
